A new class-action lawsuit from a terminal blood cancer patient claims that Celgene abused consumer safety regulations to monopolize cancer drugs.

Celgene, the manufacturer of Thalomid (thalidomide) and Revlimid (lenalidomide), blocked development of generics for the two medicines, the suit claimed.

The plaintiff and founder of the nonprofit Patients for Affordable Drugs, David Mitchell, took Revlimid to treat multiple myeloma over more than five years, while the drug’s price increased 34 percent and Mitchell’s co-pays rose 600 percent.